LBA83Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
Socinski, M, Velcheti, V, Mekhail, T, Chae, Y K, Leal, T A, Dowell, J E, Tsai, M L, Dakhil, C S, Stella, P, Shen, V, Hu, S, Paul, S M, Shames, D S, Schleifman, E, Fabrizio, D A, Nowicki, M, Yun, C, PhVolume:
30
Langue:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz394.081
Date:
October, 2019
Fichier:
PDF, 84 KB
english, 2019
File converter
Plus de résultats de recherche
More benefits 
